Q4 2024 Earnings Call Transcript March 17, 2025 FibroGen, Inc. reports earnings inline with expectations. Reported EPS is $-0 ...

Adding an immune checkpoint inhibitor (ICI) to chemotherapy for advanced prostate cancer failed to improve survival as ...

A study led by UCLA investigators shows that artificial intelligence (AI) could play a key role in improving treatment outcomes for men with prostate cancer by helping physicians determine who is most ...

A study led by UCLA investigators shows that artificial intelligence (AI) could play a key role in improving treatment ...

MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, ...

Announced sale of FibroGen China to AstraZeneca for a total consideration of approximately $160 millionTransaction expected to close by ...

Cedric Pobel, MD, covers the PEACE-1 trial of radiotherapy, standard of care, and abiraterone in low-volume metastatic castration-sensitive prostate cancer.

Patients with mCRPC prostate cancer have an elevated risk of fractures due to bone metastases and use of androgen receptor pathway inhibitors (ARPI).

Educating physicians about PSA reduction goals may increase the number of patients with mCSPC receiving first-line treatment ...

The WOLVERINE study analyzed five trials and found metastasis-directed therapy -- primarily radiation -- may delay castration resistance and improve other long-term outcomes in prostate cancer. While ...

Updated results from the TALAPRO-2 trial “support talazoparib plus enzalutamide as a standard-of-care initial treatment option for patients with mCRPC,” according to Neeraj Agarwal, MD.